share_log

Clearmind Medicine | UPLOAD: Others

Clearmind Medicine | UPLOAD: Others

Clearmind Medicine | UPLOAD：其他
美股sec公告 ·  03/21 12:44
Moomoo AI 已提取核心信息
Clearmind Medicine Inc., a company listed in the United States, received a comment from the Securities and Exchange Commission (SEC) regarding its Form 20-F filing for the fiscal year ended October 31, 2023. The SEC's correspondence, dated March 21, 2024, addressed to Chief Financial Officer Alan Rootenberg, noted the absence of required certifications by the company's principal executive officer and principal financial officer in the amendment No.1 to the Form 20-F. The SEC has requested that Clearmind Medicine amend its filing to include the updated certifications as per the Securities Exchange Act of 1934 Rule 13a-14(b) and Rule 15d-14(b), referencing the amendment. The SEC has asked for a response within ten business days or an advisory on when the company will be able to respond. The communication also mentioned that further comments may follow after the review of the company's response to this letter.
Clearmind Medicine Inc., a company listed in the United States, received a comment from the Securities and Exchange Commission (SEC) regarding its Form 20-F filing for the fiscal year ended October 31, 2023. The SEC's correspondence, dated March 21, 2024, addressed to Chief Financial Officer Alan Rootenberg, noted the absence of required certifications by the company's principal executive officer and principal financial officer in the amendment No.1 to the Form 20-F. The SEC has requested that Clearmind Medicine amend its filing to include the updated certifications as per the Securities Exchange Act of 1934 Rule 13a-14(b) and Rule 15d-14(b), referencing the amendment. The SEC has asked for a response within ten business days or an advisory on when the company will be able to respond. The communication also mentioned that further comments may follow after the review of the company's response to this letter.
在美国上市的公司Clearmind Medicine Inc. 收到了美国证券交易委员会（SEC）关于其截至2023年10月31日财年的20-F表格申报的评论。美国证券交易委员会于2024年3月21日致首席财务官艾伦·鲁滕伯格的信函指出，在20-F表格的第1号修正案中，该公司首席执行官兼首席财务官没有要求的认证。美国证券交易委员会已要求Clearmind Medicine修改其申报文件，以纳入1934年《证券交易法》第13a-14（b）条和第15d-14（b）条中引用该修正案的最新认证。美国证券交易委员会已要求在十个工作日内作出回应，或就公司何时能够做出回应提供咨询。来文还提到，在审查公司对这封信的回复后，可能会发表进一步的评论。
在美国上市的公司Clearmind Medicine Inc. 收到了美国证券交易委员会（SEC）关于其截至2023年10月31日财年的20-F表格申报的评论。美国证券交易委员会于2024年3月21日致首席财务官艾伦·鲁滕伯格的信函指出，在20-F表格的第1号修正案中，该公司首席执行官兼首席财务官没有要求的认证。美国证券交易委员会已要求Clearmind Medicine修改其申报文件，以纳入1934年《证券交易法》第13a-14（b）条和第15d-14（b）条中引用该修正案的最新认证。美国证券交易委员会已要求在十个工作日内作出回应，或就公司何时能够做出回应提供咨询。来文还提到，在审查公司对这封信的回复后，可能会发表进一步的评论。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息